The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Sanofi’s Pasteur vaccines unit and Translate Bio have expanded a collaboration to develop mRNA-based vaccines across all infectious disease areas. The deal builds on an agreement signed in 2018 ...

The Trump administration has reportedly disrupted over 100 clinical trials. Science News spoke to researchers about the impacts on four of them.

Flu vaccines reduce the risk of GP presentation with influenza by 30-60 per cent and hospitalisation with influenza by 50-70 ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing ...

Novavax's $500M Sanofi partnership with a potential $700M ... Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...